EarningsThe merger is expected to create meaningful, rapid accretion, with EPS accretive in Year 1.
Revenue StreamsThe merger with Becton Dickinson’s Biosciences & Diagnostic Solutions Business is expected to give Waters Corp more exposure to durable recurring revenue streams, increasing annual recurring revenues to over 70%.
SynergiesThe transaction is expected to generate significant synergies, including $290 million in revenue synergies by year five post-closing and $200 million in cost synergies by year three post-closing.